Local application of CpG oligodeoxynucleotide enhances nontypeable Haemophilus influenzae-specific mucosal IgA responses in the middle ear

Acta Oto-Laryngologica

Volumn 127, Issue 8, 2007, Pages 809-815

  Kodama, Satoru ^a   Hirano, Takashi ^a   Abe, Nobuyuki ^a   Suzuki, Masashi ^a  

^a OITA UNIVERSITY   (Japan)

Author keywords

CpG; Middle ear; Mucosal immunity; NTHi; P6

Indexed keywords

BACTERIAL PROTEIN; CPG OLIGODEOXYNUCLEOTIDE; IMMUNOGLOBULIN A; PROTEIN P6; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; ANTIBODY PRODUCING CELL; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; HAEMOPHILUS INFLUENZAE TYPE A; IMMUNOGLOBULIN PRODUCTION; IMMUNOREGULATION; INFECTION PREVENTION; MIDDLE EAR MUCOSA; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; OTITIS MEDIA; PRIORITY JOURNAL; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, TOPICAL; ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, VIRAL; BACTERIAL OUTER MEMBRANE PROTEINS; DISEASE MODELS, ANIMAL; EAR, MIDDLE; ENZYME-LINKED IMMUNOSORBENT ASSAY; HAEMOPHILUS INFLUENZAE; HAEMOPHILUS VACCINES; IMMUNITY, CELLULAR; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; MUCOUS MEMBRANE; OLIGODEOXYRIBONUCLEOTIDES; OTITIS MEDIA; TREATMENT OUTCOME; VACCINATION;

EID: 34548355236     PISSN: 00016489     EISSN: 16512553     Source Type: Journal    
DOI: 10.1080/00016480601075365     Document Type: Article

References (15)

1. Murphy TF. Respiratory infections caused by non-typeable Haemophilus influenzae. Curr Opin Infect Dis 2003;16:129-34.
2. Lim DJ, Chun YM, Lee HY, Moon SK, Chang KH, Li JD, et al. Cell biology of tubotympanum in relation to pathogenesis of otitis media - a review. Vaccine 2000;19(Suppl):S17-25.
3. Poolman JT, Bakaletz L, Cripps AW, Denoel PA, Forsgren A, Kyd J, et al. Developing a nontypeable Haemophilus influenzae (NTHi) vaccine. Vaccine 2000;19(Suppl):S108-15.
4. Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 2002;20:709-60.
5. Klinman DM, Yi AK, Beaucage SL, Conover J, Krieg AM. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon γ. Proc Natl Acad Sci USA 1996;93:2879-83.
6. Halpern MD, Kurlander RJ, Pisetsky DS. Bacterial DNA induces murine interferon-γ production by stimulation of interleukin-12 and tumor necrosis factor-α. Cell Immunol 1996;167:72-8.
7. Sparwasser T, Koch ES, Vabulas RM, Heek K, Lipford GB, Ellwart JW, et al. Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. Eur J Immunol 1998;28:2045-54.
8. Kiyono H, Fukuyama S. NALT versus Peyer's-patch-mediated mucosal immunity. Nat Rev Immunol 2004;4:699-710.
9. Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat Med 2005;11(Suppl):S45-53.
10. Kodama S, Suenaga S, Hirano T, Suzuki M, Mogi G. Induction of specific immunoglobulin A and Th2 immune responses to P6 outer membrane protein of nontypeable Haemophilus influenzae in middle ear mucosa by intranasal immunization. Infect Immun 2000;68:2294-300.
11. Sabirov A, Kodama S, Hirano T, Suzuki M, Mogi G. Intranasal immunization enhances clearance of nontypeable Haemophilus influenzae and reduces stimulation of tumor necrosis factor alpha production in the murine model of otitis media. Infect Immun 2001;69:2964-71.
12. Abe N, Kodama S, Hirano T, Eto M, Suzuki M. Nasal vaccination with CpG oligodeoxynucleotide induces protective immunity against nontypeable Haemophilus influenzae in the nasopharynx. Laryngoscope 2006;116:407-12.
13. Harabuchi Y, Faden H, Yamanaka N, Duffy L, Wolf J, Krystofik D. Nasopharyngeal colonization with nontypeable Haemophilus influenzae and recurrent otitis media. J Infect Dis 1994;170:862-6.
14. Klinman DM. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev Immunol 2004;4:1-10.
15. Kodama S, Abe N, Hirano T, Suzuki M. Safety and efficacy of nasal application of CpG oligodeoxynucleotide as a mucosal adjuvant. Laryngoscope 2006;116:331-5.